GKOS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$199.31median target· current $164.89 (+20.9%)14 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 1666.67
EPS (TTM)$-3.261896.0% YoY
Profit margin-30.7%HEALTHCARE
Market cap$9.72BMid cap
Valuation
- Forward P/E
- 1666.67
- PEG ratio
- 1.64
- P/B
- 13.27
- P/S (TTM)
- 15.87
- EV/EBITDA
- -57.89
Profitability & growth
- ROE (TTM)
- -26.0%
- Operating margin
- -8.5%
- Revenue growth YoY
- 49.5%
- Dividend yield
- —
- Beta
- 0.69
Last earnings
Jul 29, 2026 · Estimate $-0.28 · Reported $-0.14
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Glaukos Corp
Company profileGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ONE GLAUKOS WAY, ALISO VIEJO, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$9.72B
Shares outstanding$59.0M
52W high$191.62
52W low$73.16
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent